Suppr超能文献

非酒精性脂肪性肝病与 HIV:性、种族和民族能解释与 HIV 相关的风险吗?

NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?

机构信息

School of Medicine, University of Colorado-Anschutz Medical Campus, Aurora, CO, USA.

Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

出版信息

Curr HIV/AIDS Rep. 2018 Jun;15(3):212-222. doi: 10.1007/s11904-018-0392-1.

Abstract

PURPOSE OF REVIEW

Here, we review the epidemiology, diagnosis, and management of non-alcoholic fatty liver disease (NAFLD) in the general population, discuss HIV-specific differences in NAFLD pathogenesis, and summarize what is known regarding differences in NAFLD by race/ethnicity and sex.

RECENT FINDINGS

The reported prevalence of NAFLD among people living with HIV varies by age, body mass index, comorbidity, and method of NAFLD diagnosis, but is generally thought to be greater among HIV-infected compared to HIV-uninfected populations. Minorities and women tend to experience poorer HIV treatment outcomes (Meditz et al. J Infect Dis. 203(4):442-51, 2011; Beer et al. Medicine (Baltimore). 95(13):e 3171, 2016; Gant et al. MMWR Morb Mortal Wkly Rep. 66(40):1065-72, 2017; Millett et al. Lancet. 380(9839):341-8, 2012; Wejnert et al. J Infect Dis. 213(5):776-83, 2016), and are at the greatest risk for significant weight gain with HIV treatment (Erlandson et al. Medicine (Baltimore). 95(46):e 5399, 2016). Thus, women and minorities living with HIV may be at a higher risk of developing NAFLD and progressive liver disease. Disparities in the diagnosis, progression, and prognosis of NAFLD and HIV-associated NAFLD may be, in part, explained by genetic and sex differences; however, data is limited.

摘要

目的综述

本文综述了普通人群中非酒精性脂肪性肝病(NAFLD)的流行病学、诊断和管理,讨论了 HIV 特异性 NAFLD 发病机制的差异,并总结了种族/民族和性别差异对 NAFLD 的影响。

最近的发现

在 HIV 感染者和 HIV 未感染者中,NAFLD 的报告患病率因年龄、体重指数、合并症和 NAFLD 诊断方法而异,但一般认为 HIV 感染者中的患病率高于 HIV 未感染者。少数族裔和女性往往 HIV 治疗效果较差(Meditz 等人,J Infect Dis. 203(4):442-51, 2011;Beer 等人,Medicine (Baltimore). 95(13):e 3171, 2016;Gant 等人,MMWR Morb Mortal Wkly Rep. 66(40):1065-72, 2017;Millett 等人,Lancet. 380(9839):341-8, 2012;Wejnert 等人,J Infect Dis. 213(5):776-83, 2016),并且在 HIV 治疗中体重增加的风险最大(Erlandson 等人,Medicine (Baltimore). 95(46):e 5399, 2016)。因此,HIV 感染者中的女性和少数族裔可能面临更高的 NAFLD 和进展性肝病的风险。NAFLD 和 HIV 相关 NAFLD 的诊断、进展和预后的差异部分可能是由遗传和性别差异造成的;然而,数据有限。

相似文献

1
NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?
Curr HIV/AIDS Rep. 2018 Jun;15(3):212-222. doi: 10.1007/s11904-018-0392-1.
2
Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV.
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):211-223. doi: 10.1016/S2468-1253(16)30120-0. Epub 2017 Feb 9.
3
Indian patients with human immunodeficiency virus infection have high prevalence but mild severity of non-alcoholic fatty liver disease.
Diabetes Metab Syndr. 2022 Dec;16(12):102679. doi: 10.1016/j.dsx.2022.102679. Epub 2022 Nov 23.
6
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Lancet Gastroenterol Hepatol. 2020 Aug;5(8):739-752. doi: 10.1016/S2468-1253(20)30077-7. Epub 2020 May 12.
9
Serum 25-hydroxyvitamin-D and nonalcoholic fatty liver disease: Does race/ethnicity matter? Findings from the MESA cohort.
Nutr Metab Cardiovasc Dis. 2020 Jan 3;30(1):114-122. doi: 10.1016/j.numecd.2019.09.004. Epub 2019 Sep 10.
10
Fatty liver disease in persons with HIV infection.
Top Antivir Med. 2019 May;27(2):75-82.

引用本文的文献

2
MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls.
Aliment Pharmacol Ther. 2024 Nov;60(10):1351-1360. doi: 10.1111/apt.18236. Epub 2024 Sep 5.
3
A review of dolutegravir-associated weight gain and secondary metabolic comorbidities.
SAGE Open Med. 2024 Jun 13;12:20503121241260613. doi: 10.1177/20503121241260613. eCollection 2024.
5
Adipose Tissue Dysfunction and Energy Balance Paradigms in People Living With HIV.
Endocr Rev. 2024 Mar 4;45(2):190-209. doi: 10.1210/endrev/bnad028.
7
HIV-HBV Coinfection-Current Challenges for Virologic Monitoring.
Biomedicines. 2023 Apr 28;11(5):1306. doi: 10.3390/biomedicines11051306.
8
Prevalence and dynamics of NAFLD-associated fibrosis in people living with HIV in Vienna from first presentation to last follow-up.
Wien Klin Wochenschr. 2023 Aug;135(15-16):420-428. doi: 10.1007/s00508-022-02133-9. Epub 2022 Dec 28.
9
Heightened levels of plasma growth differentiation factor 15 in men living with HIV.
Physiol Rep. 2022 May;10(9):e15293. doi: 10.14814/phy2.15293.
10
Sex Differences in Non-AIDS Comorbidities Among People With Human Immunodeficiency Virus.
Open Forum Infect Dis. 2021 Nov 3;8(12):ofab558. doi: 10.1093/ofid/ofab558. eCollection 2021 Dec.

本文引用的文献

1
Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
Aliment Pharmacol Ther. 2018 Jan;47(2):192-202. doi: 10.1111/apt.14397. Epub 2017 Oct 30.
4
HIV Care Outcomes Among Hispanics or Latinos with Diagnosed HIV Infection - United States, 2015.
MMWR Morb Mortal Wkly Rep. 2017 Oct 13;66(40):1065-1072. doi: 10.15585/mmwr.mm6640a2.
7
Noninvasive Tests Do Not Accurately Differentiate Nonalcoholic Steatohepatitis From Simple Steatosis: A Systematic Review and Meta-analysis.
Clin Gastroenterol Hepatol. 2018 Jun;16(6):837-861. doi: 10.1016/j.cgh.2017.08.024. Epub 2017 Aug 22.
8
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
Hepatology. 2018 May;67(5):1754-1767. doi: 10.1002/hep.29477. Epub 2018 Jan 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验